|
|
Article: DuPont Merck Responds To Patent Office Action On Ultrasound Contrast Patents
- Article from:
- PR Newswire
- Article date:
- May 6, 1998
CopyrightCOPYRIGHT 1998 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
N.BILLERICA, Mass., May 6 /PRNewswire/ -- The DuPont Merck Pharmaceutical Company announced today that the U.S. Patent Office has issued an office action rejecting some of the claims covered by U.S. Patents 5,547,656 and 5,527,521 owned by ImaRx Pharmaceutical Corporation and licensed to DuPont Merck. These patents cover, among other things, low-density, perfluorocarbon gas-filled microspheres used for medical imaging. DuPont Merck and ImaRx fully expect the patents to be found valid and enforceable upon standard re- examination of the patent claims in question. According to the U.S. Patent Office, nearly 80 percent of patents subjected to re-examination in the U.S. ...